Study Finds Few Ethnic Differences in Prostate Cancer Genomics

A 350-patient analysis presented at an ESMO congress compared tissue and liquid biopsy results across ethnic groups in advanced prostate cancer.

Updated on Nov. 17, 2026 in Cancer

Clear unlabeled glass sample vials in a stainless-steel rack on a laboratory bench, with a blurred centrifuge behind in cool even light.
A 350-patient analysis presented at an ESMO congress found no significant ethnic differences in actionable genomic alterations among men with advanced prostate cancer. AI Illustration. Upload story photo >

Researchers presented an analysis of 350 patients with metastatic castration-resistant prostate cancer at an ESMO congress, finding no statistically significant ethnic differences in actionable genomic alterations, tumor mutational burden, or circulating tumor DNA fraction. All patients had received one line of androgen receptor pathway inhibitor and then progressed.

Why it matters

Ethnicity differences in prostate cancer were previously known, so the findings add evidence on how genomic testing results may compare across diverse patient populations. The results also bear on how tissue and liquid biopsies can complement each other when selecting targeted therapies.

The analysis covered 350 patients with metastatic castration-resistant prostate cancer, with paired tissue and ctDNA samples available for 101 of them. ctDNA fractions were higher than tissue-based mutational burden values, but the single-center design leaves wider ethnic representation untested.

The players

ESMO (European Society for Medical Oncology)

ESMO is a professional society of medical oncologists that holds an annual congress presenting cancer research worldwide.

Guy's Hospital

Guy's Hospital is a major teaching hospital in London whose diverse patient population was the single site for this analysis.

The details

Researchers analyzed tissue and ctDNA samples from each patient to identify actionable mutations and compared tumor mutation burden and ctDNA fractions across ethnic groups. TP53 was the most frequently observed mutation with no ethnicity differences, while BRCA and aggressive mutations showed high tissue-ctDNA concordance and PTEN mutations were mainly detected by ctDNA.

Timeline

  1. This year: analysis of 350 patients presented at the ESMO congress

Health Landscape

Earlier research had documented ethnicity differences in prostate cancer genomics, which made this analysis of a diverse London cohort a test of whether those differences hold across tissue and liquid biopsies. The finding of no significant ethnic differences in actionable alterations places it alongside efforts to make precision oncology apply equitably across populations.

For men with advanced prostate cancer, the findings suggest that comparing tissue and liquid biopsy results may help identify targeted drug options regardless of ethnic background. The researchers hope the two testing methods can help each other pinpoint the most actionable mutations in the future.

The takeaway

Liquid and tissue biopsies capture different mutations, so using both may give a fuller picture of a tumor than either alone. Patients and clinicians should discuss which testing approach fits the disease's stage and available treatments.

Further reading

Explore more on Cancer research and treatment developments.

Source note: This article includes information reported by MedPage Today.